Recommendations for Titration and Administration of Oral Semaglutide for the Treatment of Type 2 Diabetes during Ramadan

• Published in: Dubai Diabetes and Endocrinology
• Main Author: Hassanein M.; Almansari A.; Ba-Essa E.; Alawadi F.F.; Elbadawi H.; Sahay R.K.; Malik R.; Abdul Ghani R.; Abusnana S.; Shaikh S.; Zainudin S.B.; Elhadd T.; Al Saleh Y.
• Format: Review
• Language: English
• Published: S. Karger AG 2022
• Online Access: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85198014844&doi=10.1159%2f000527475&partnerID=40&md5=ae23fc9ac69a9da02608be1dbf55cbda
• ISSN: 26731797
• DOI: 10.1159/000527475

Background: Injectable glucagon-like peptide-1 receptor agonists (GLP-1RAs) are proven to be well tolerated and efficacious in people with type 2 diabetes mellitus (T2DM) fasting during Ramadan. The first oral GLP-1RA semaglutide, also indicated for the treatment of T2DM, has specific dosing instructions to optimize treatment exposure, which may need to be altered during Ramadan fasting to ensure optimal efficacy. Summary: Given the lack of current published evidence for the effect of oral semaglutide during Ramadan, a panel of experts formulated recommendations for the administration of oral semaglutide during Ramadan. Key Messages: This statement reports recommendations for oral semaglutide administration during Ramadan. © 2022 The Author(s). Published by S. Karger AG, Basel.